Seprafilm in Open Abdomens: a Study of Wound and Adhesion Characteristics in Trauma Damage Control Patients (OASIT)

October 17, 2017 updated by: Stan Stawicki

Seprafilm in Open Abdomens: a Prospective Evaluation of Wound and Adhesion Characteristics in Trauma Damage Control (OASIT)

The goal of this study is to test the effects of Seprafilm adhesion barrier on patients who are undergoing open abdomen damage control management for traumatic injuries when compared to no adhesion barrier use. Specifically, the researchers wish to study the effects of Seprafilm adhesion barrier on:

  • the number and intensity of adhesions,
  • whether there is any difference between treatment groups (Seprafilm vs. no Seprafilm) who go on to successful definitive abdominal closure,
  • rate of occurrence of secondary complications (such as abscesses) associated with short- and long-term beneficial effects of reducing adhesion formation,and
  • whether there is any difference between treatment groups regarding patient functional recovery.

Study Overview

Status

Completed

Intervention / Treatment

Detailed Description

Data to be analyzed includes:

Age, gender, traumatic injuries, trauma alert level, procedure information, length of hospital stay, length of ICU stay, interval between admission and initial operation, interval between operations, whether operation took place during the day or night, duration of operation in minutes, number of surgeons present during the operation, description of the initial operation, justification for using damage control approach, complications noted, injuries missed or delayed in diagnosis, Acute Physiology and Chronic Health Evaluation II (APACHE II) calculations at various time points, Simplified Acute Physiology Score (SAPS II) calculations at various time points, Glasgow Coma Score (GCS) calculations at various time points, changes in GCS at over time, Injury Severity Score (ISS) at various time points, Abbreviated Injury Scale (AIS) at various time points, Penetrating Abdominal Trauma Index score (if applicable) at various time points, complete blood count (CBC) results at various time points, blood chemistry results at various time points, blood gas results at various time points, subject randomization information, number of operations, adhesion scores (Zuhlke and Yaacobi) for each operative procedure, contamination score for each operative procedure, diagnosis and description of sub-procedures for each operative procedure, wound characteristics from the start and end of all operative procedures (e.g. length and width of the fascia and skin), type of abdominal coverage or closure, discharge destination (e.g. home, short term rehabilitation facility, etc.), Functional Outcome Measure score, Glasgow Outcome Score (GOS) at various time points, number and interval of post discharge follow-up visits, wound characteristics since discharge at several time points and complications/complaints noted since discharge at several time points.

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • New Jersey
      • Camden, New Jersey, United States, 08103
        • Cooper University Hospital
    • North Carolina
      • Charlotte, North Carolina, United States, 32861
        • Carolinas Medical Center
    • Ohio
      • Columbus, Ohio, United States, 43210
        • The Ohio State University Medical Center
    • Pennsylvania
      • Bethlehem, Pennsylvania, United States, 18015
        • St. Luke's Hospital
      • Philadelphia, Pennsylvania, United States, 19107
        • Thomas Jefferson University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 89 years (ADULT, OLDER_ADULT)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Trauma patients undergoing DC/OA management for traumatic injury
  • Age 18+
  • Life expectancy longer than 48 hours

Exclusion Criteria:

  • Prisoners
  • Pregnant patients
  • Younger than 18 years of age

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: TREATMENT
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: SINGLE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
OTHER: Seprafilm
The treatment group will receive Seprafilm while the control group will not receive Seprafilm. Allocation of patients will be in 1:1 ratio.

Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:

  • Two Seprafilm pieces between the liver and the anterior abdominal wall
  • Four pieces over the exposed bowel surfaces anteriorly
  • Two slightly staggered pieces of Seprafilm in each colic gutter
  • Two pieces in the pelvic area.
  • If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair.
NO_INTERVENTION: No Seprafilm
This group will be treated according to the current standard of care. No seprafilm will be applied in this subset of patients.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Adhesion Characteristics
Time Frame: Up to 1 year

Zuhlke adhesion score (1 - minimum to 4 - maximum)

  1. = filmy adhesions, easy to separate by blunt dissection
  2. = stronger adhesions; blunt dissection possible, partly sharp dissection necessary; beginning of vascularization
  3. = strong adhesions; lysis possible by sharp dissection only; clear vascularization
  4. = very strong adhesions; lysis possible by sharp dissection only; organs strongly attached with severe adhesions; damage to organs hardly preventable
Up to 1 year

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Wound Healing Characteristics
Time Frame: Participants will be followed until their open abdomen is closed. Depending on the nature and severity of the wound, this period may last as long as 1 year after the patient has been discharged.
There will not be a fixed duration of outpatient follow-up (fixed follow-up in trauma patients is not practical due to the unpredictable nature of trauma population), an average (mean) follow-up will be determined for the entire cohort of patients for the purposes of the study, up to a maximum of 1 year (if available) following hospital discharge.
Participants will be followed until their open abdomen is closed. Depending on the nature and severity of the wound, this period may last as long as 1 year after the patient has been discharged.

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Patient Mortality
Time Frame: 28 days & end of follow-up
Assessment of patient mortality at 28 days, with subsequent determination of survival (i.e., patient status at last known follow-up)
28 days & end of follow-up
Enterocutaneous and Other Fistula
Time Frame: Up to 1 year post-injury
Determination of enterocutaneous/other fistula among study patients during the hospitalization and the follow-up interval
Up to 1 year post-injury
Ventral Hernia
Time Frame: Up to 1 year follow-up
Determination of ventral hernia presence during follow-up visits
Up to 1 year follow-up
Infection / Abscess / Sepsis
Time Frame: Up to 1 year
Assessment of any infection, abscess, or sepsis during the initial and the follow-up periods
Up to 1 year
Bowel Obstruction
Time Frame: Up to 1 year follow-up
Determination of bowel obstruction during the entire available study follow-up period
Up to 1 year follow-up
Patient Functional Outcomes
Time Frame: Up to 1 year follow-up

Assessment of Glasgow Outcome Scale (GOS) and the Functional Outcome Measures (FOM) during the available follow-up period.

FOM Source: [1] Ohio Dept of Public Safety. Ohio Trauma Registry Data Dictionary. Columbus: 2004.

FOM Scale range: 1 (worst) to 4 (best); GOS Scale: 1 (worst) to 5 (best)

FOM Feeding Subscale

  1. Fully dependent
  2. Partially dependent
  3. Independent w/device
  4. Fully independent

FOM Locomotion Subscale

  1. Fully dependent
  2. Partially dependent
  3. Independent w/device
  4. Fully independent

FOM Expression/Communication Subscale

  1. Fully dependent
  2. Partially dependent
  3. Independent w/device
  4. Fully independent

Glasgow Outcome Scale:

  1. Death
  2. Persistent vegetative state: Minimal responsiveness
  3. Severe disability: Conscious but disabled; dependent on others for daily support
  4. Moderate disability: Disabled but independent; can work in sheltered setting
  5. Good recovery: Resumption of normal life despite minor deficits
Up to 1 year follow-up
Would Complication
Time Frame: Up to 1 year follow-up period
Tracking of wound infection, dehiscence, hernia, or any other would-related complication of complaint
Up to 1 year follow-up period

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Principal Investigator: Stanislaw P Stawicki, MD, Ohio State University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

April 1, 2010

Primary Completion (ACTUAL)

September 1, 2013

Study Completion (ACTUAL)

December 1, 2013

Study Registration Dates

First Submitted

January 5, 2012

First Submitted That Met QC Criteria

May 7, 2012

First Posted (ESTIMATE)

May 9, 2012

Study Record Updates

Last Update Posted (ACTUAL)

November 20, 2017

Last Update Submitted That Met QC Criteria

October 17, 2017

Last Verified

October 1, 2017

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

Currently, the only available data is de-identified dataset without any linkages to the original data. Data storage currently past record-keeping requirements. Study was permanently closed in June 2014.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Trauma

Clinical Trials on Seprafilm

3
Subscribe